Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: Putative mechanisms of failure

Drugs

Volumn 67, Issue 11, 2007, Pages 1521-1530

  Fass, Ronnie ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

COMORBIDITY; DRUG MEGADOSE; ENTEROPATHY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; HYPERALGESIA; MENTAL DISEASE; REVIEW; STOMACH EMPTYING; TREATMENT FAILURE;

GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC EMPTYING; GASTROESOPHAGEAL REFLUX; HUMANS; INFLAMMATORY BOWEL DISEASES; PROTON PUMPS; STRESS, PSYCHOLOGICAL; TREATMENT FAILURE;

EID: 34547934691     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767110-00001     Document Type: Review

References (60)

1. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 May; 112 (5): 1448-56
2. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completed relieved with PPIs. Am J Gastroenterol 2003; 98 (9): 1940-4
3. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of 56 treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10 (2): 119-24
4. Fass R, Shapiro M, Dekel R, et al. Proton pump inhibitor failure in reflux disease: where next? Aliment Pharmacol Ther 2005; 22 (2): 79-94
5. Vaezi MF. 'Refractory GERD': acid, nonacid, or not GERD? Am J Gastroenterol 2004; 99 (6): 989-90
6. Richter JE, Bochenek W. Pantoprazole US GERD Study Group. Oral pantoprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Am J Gastroenterol 2000; 95 (11): 3071-80
7. Johnson DA, Lauritsen K, Junghard O, et al. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy [abstract no. T1646]. Gastroenterology 2003; 124 (4 Suppl.): A540
8. Fass R, Thomas S, Traxler D, et al. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI versus switching to a different PPI [abstract no. 326]. Gastroenterology 2004; 146 (4 Suppl. 2): A37
9. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40mg once a day is equally effective as lansoprazole 30mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy: a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14 (12): 1595-603
10. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2 (8): 656-64
11. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32 (10): 974-9
12. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51(6): 885-92
13. Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995; 9 (2): 145-51
14. Castell DO, Richter JE, Robinson R, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91 (9): 1749-57
15. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15 (2): 227-31
16. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared to omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96 (3): 656-65
17. Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998; 12 (9): 893-7
18. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14 (5): 597-602
19. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994; 89 (10): 1844-8
20. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44 (6): 700-5
21. Gallup Study of Consumers' use of Stomach Relief Products. Princeton (NJ): The Gallup Organization, 2000
22. Vela M, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120 (7): 1599-606
23. Bredenoord A, Weusten B, Curvers W, et al. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313-8
24. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006 Oct; 55 (10): 1398-402
25. Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20 (1): 81-8
26. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17 (4): 537-45
27. Watson RG, Tham TC, Johnston BT, et al. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux: the "sensitive oesophagus". Gut 1997; 40 (5): 587-90
28. Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97 (8): 1901-9
29. Hobson AR, Matthews P, Furlong P, et al. The role of esophageal afferent pathway sensitivity in non-erosive reflux disease [abstract no. 128]. Gastroenterology 2004; 126 (4 Suppl. 2): A18
30. Shapiro M, Green C, Bautista J, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006 May; 101 (5): 1084-91
31. Vaezi MF. Duodenogastroesophageal reflux. In: Castro D, Richter J, editors. The oesophagus. Philadelphia (PA): Lippincott Williams & Wilkins, 2004: 1553-8
32. Netzer P, Gut A, Brundler R, et al. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001; 15 (9): 1375-84
33. Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998; 43 (5): 603-6
34. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99 (6): 981-8
35. Siddiqui A, Rodriguez-Stanley S, Zubaidi S, et al. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50 (1): 81-5
36. Kudara N, Chiba T, Orii S, et al. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy [abstract no. 23]. Neurogastroenterol Motil 2004; 16 (5): 654
37. Sotoudehmanesh R, Ali Asgari A, Ansari R, et al. Endoscopic findings in end-stage renal disease. Endoscopy 2003; 35 (6): 502-5
38. Cucchiara S, Minella R, Campanozzi A, et al. Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig Dis Sci 1997; 42 (2): 293-9
39. Liacouras CA, Campbell C, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3: 1198-206
40. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone proprionate. Gastrointest Endosc 2006; 63: 3-12
41. Straumann A, Spichtin H-P, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660-9
42. Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003; 58: 516-22
43. Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique eseophageal features. Gastrointest Endosc 2004; 59: 355-61
44. Zimmerman SL, Levine MS, Rubesin SE, et al. Idiopathic eosinophilic esophagitis in adults: the ringed esophagus. Radiology 2005; 236: 159-65
45. Johnston BT, Lewis S, Collins J, et al. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995; 30: 1-5
46. Nojkov B, Chey W, Adlis S, et al. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease [abstract]. Gastroenterology 2005; 128 (4 Suppl. 2): A61
47. Delhotal-Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drub Metab Pharmacokinet 1991; Spec No 3: 315-20
48. Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11 (2): 359-64
49. Leite L, Lambrecht N, Sachs G, et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? [abstract]. Gastroenterology 1995; 108: A147
50. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72 (4): 453-60
51. Kawamura M, Ohara S, Koike T, et al. The effect of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73
52. Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17 (12): 1521-8
53. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93 (5): 763-7
54. Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98 (3): 545-50
55. Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13 (11): 1467-71
56. Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16 (7): 1309-16
57. Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17 (12): 1553-8
58. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36 (4): 539-43
59. Vigneri S, Termini R, Savarino V, et al. Review article: is Helicobacter pylori status relevant to the management of GORD? Aliment Pharmacol Ther 2000; 14 Suppl. 3: 31-42
60. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117 (1): 11-6